Pharmaceutical packaging equipment refers to the equipment comprised of multiple equipment and its components, piping, instruments, electrical items and other related accessories which are all fabricated and assembled at the shop and usually mounted on the skid which are ready for connection and used for packaging of all pharmaceutical products, using flexible, and heat sealable material to form packages that are filled with a product and then sealed. The main types of products of pharmaceutical packaging equipment are primary packaging equipment, secondary packaging equipment, and labeling and sterilization equipment. Primary packaging equipment is in direct contact with the product itself and is referred to as a consumer unit. Primary packaging is what directly encases and contains the drug product. Secondary packaging equipment provides corrugated cardboard packaging print finished to a high standard. Secondary packaging is the exterior packaging of the primary packaging that groups packages and further protects or labels the drug product. Labeling and sterilization equipment is responsible for adding directions of use and sterilizing the packaging environment. The various types of pharmaceutical packaging equipment are blenders, granulators, tablet pressers, tablet coating machines, and allied machines. The pharmaceutical packaging equipment market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical packaging equipment market statistics, including pharmaceutical packaging equipment industry global market size, regional shares, competitors with a pharmaceutical packaging equipment market share, detailed pharmaceutical packaging equipment market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical packaging equipment industry. This pharmaceutical packaging equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pharmaceutical packaging equipment market size grew from $9.94 billion in 2022 to $11.06 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical packaging equipment market size is expected to grow to $16.34 billion in 2027 at a CAGR of 10.2%. An increase in ageing population is expected to increase the prevalence of age-related ailments, thus contributing to the growth of the pharmaceutical drugs and pharmaceutical packaging equipment market. The elderly population is increasing rapidly across the world, and it is expected to continue over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC) report, the population aged 65 years and above is expected to reach approximately 71 million by 2030 and 98 million by 2060 in the USA. It is estimated by 2030, China will have nearly half of the Parkinson’s disease population in the world, which can be attributed to the country’s aging population. This expected increase in the aging population suffering from age-related ailments is projected to drive the pharmaceutical packaging equipment market. The automatic packaging machine is increasingly utilized in the pharmaceutical packaging equipment market. The machine automatically supplies packing materials and contents, and other machines of the packaging process can be done automatically. For instance, in July 2020, OPTIMA Packaging Group, a Germany based company that designs and builds packaging equipment for pharmaceutical, consumer, nonwovens, and life science products, launched OPTIMA FPA. It is a unique platform that can assemble pen injectors both fully or semi-automatically. It is especially suitable as an entry-level system. Another new feature of the Optima FPA is the choice of adding a printer connected with 360-degree labeling. This product launch has increased the company’s automated packaging solutions portfolio. In February 2021, ProMach, a US-based packaging machinery company, acquired Serpa Packaging Solutions for an undisclosed amount. The addition of Serpa brings automated cartoning systems into ProMach’s portfolio and significantly expands ProMach’s specialized secondary packaging machinery and line integration capabilities for the rapidly growing pharmaceutical industry. Serpa Packaging Solutions is a US-based company that designs and manufactures pharmaceutical packaging equipment. Major players in the pharmaceutical packaging equipment market are Körber AG, Uhlmann Group, Marchesini Group S.p.A., Optima Packaging Group, Romaco Holding GmbH, MG2 s.r.l., Robert Bosch GmbH, Industria Macchine Automatiche S.p.A., Vanguard Pharmaceutical Machinery, Accutek Packaging Equipment Companies, MULTIVAC Group, Bausch + Ströbel Maschinenfabrik Ilshofen GmbH + Co. KG, ACG Group, Coesia S.P.A., Syntegon Technology, Trustar Pharma & Packing Equipment, Inline Filling Systems, Dara Pharmaceutical Packaging, ARPAC LLC, Romaco Group, N.K.P. Pharma, Ropack, and Trustar Pharma & Packing Equipment. North America was the largest region in the pharmaceutical packaging equipment market in 2022. Asia-Pacific was the second-largest market in the pharmaceutical packaging equipment market. The regions covered in the pharmaceutical packaging equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pharmaceutical packaging equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The pharmaceuticals packaging equipment market consists of sales of accumulating and collating machines, blister packs, skin packs and vacuum packaging machines, bottle caps equipment, over-capping, lidding, closing, seaming and sealing machines, box, case, tray, and carrier forming, packing, unpacking, closing, and sealing machines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical packaging equipment market is segmented - 1) By Product: Primary Packaging Equipment, Secondary Packaging Equipment, Labelling And Sterialization Equipment 2) By Packaging Type: Liquids Packaging Equipment, Solid Packaging Equipment, Semi-Solid Packaging Equipment 3) By Equipment Type: Blenders, Granulators, Tablet Pressers, Tablet Coating Machine, Allied Machines 4) By Mode of Administration: Injectable Administration, Topical Administration, Oral Administration

Pharmaceutical drug refers to a substance created to treat, prevent, or cure an illness or other condition, or to lessen its symptoms. To list the most popular methods, drugs can be consumed orally, through a skin patch, by injection, or through an inhaler. Other vital medications made from natural materials include vaccinations, steroid hormones, human blood-plasma fractions, and antibiotics. The main types of pharmaceutical drugs are cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorders drugs, musculoskeletal disorders drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs. Cardiovascular drugs are used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The pharmaceutical drug market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical drug market statistics, including pharmaceutical drug industry global market size, regional shares, competitors with a pharmaceutical drug market share, detailed pharmaceutical drug market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical drug industry. This pharmaceutical drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical drugs market is expected to grow from $ 1,136.23 billion in 2022 to $1,199.86 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The pharmaceutical drugs market is expected to reach $1,848.49 billion in 2027 at a CAGR of 11.4%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. China and India together had about 193.4 million diabetic patients in 2019 and India is expected to have about 101 million diabetic patients by 2030, thereby increasing the need for biologics drugs for diabetic patients. These factors are expected to increase the patient pool globally, thereby driving the pharmaceutical drug market during the forecast period. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period, this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research, and development of new products. For instance, the US interest rates rose to 3.5% by 2021. These factors are expected to hurt the market as borrowing money becomes expensive, thereby affecting the pharmaceuticals market growth. Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company. For example, in 2020, FDA has switched three prescription drugs to OTC including Voltaren for arthritis pain, olopatadine hydrochloride 0.1% and 0.2% (Pataday Twice Daily Relief and Pataday Once Daily Relief) for temporary relief of itchy and red eyes due to pollen, ragweed, and grass. Major companies in the pharmaceutical drugs market include Bristol-Myers Squibb, Sanofi S.A, Johnson & Johnson, Novartis AG, Bayer AG, Abbott Laboratories, GlaxosmithKline, AstraZenec, Merck & Co and CJ Corp. North America was the largest region in the pharmaceutical drugs market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The pharmaceutical drug market consists of sales of generic drugs, over-the-counter medications, bulk drugs, vaccines, biosimilars, and biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical drugs market is segmented - 1) By Type: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs), Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases, Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals, Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs For Infections And Others, Drugs For Hormonal Replacement Therapy, Diuretics, Blood Products, Anemia And Other Blood Disorder Drugs, Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal), Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism), Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs, Analgesics, Anti-Parkinson drugs, Anesthetics, Anti-Epileptics, Other CNS drugs, Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma), Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy), Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations

Glass curtain walls are aluminum-framed lighter weight facades that house glass or metal panels. These glazing systems are incapable of supporting the weight of a roof or floor. Glass curtain walls are frequently used as part of a building envelope or as a component of a wall system. These are used to keep air and water out of the building, essentially acting as a buffer and an insulator. The main system types of glass curtain wall are unitized, and stick. The unitized glass curtain wall refers to curtain systems made of large glass units that are assembled and glazed in the factory and then shipped to the construction site. The various end-uses include commercial, public, and residential in applications such as exterior glazed, interior glazed. The glass curtain wall market research report is one of a series of new reports from The Business Research Company that provides glass curtain wall market statistics, including glass curtain wall industry global market size, regional shares, competitors with a glass curtain wall market share, detailed glass curtain wall market segments, market trends and opportunities, and any further data you may need to thrive in the glass curtain wall industry. This glass curtain wall market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global glass curtain wall market size grew from $52.9 billion in 2022 to $58.45 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The glass curtain wall market size is expected to grow to $86.59 billion in 2027 at a CAGR of 10.3%. The rise in consumer spending on home remodelling is significantly driving the growth of the glass curtain wall market. As the glass curtain walls provide completely refurbished modern looks for the aged buildings and houses with seamlessly incorporated designs and patterns, the consumers have started spending more on them to get more enhanced looks for their homes. For instance, according to the Home Advisor survey, the mean household spending on home services in the United States increased to $13,138 in 2020, which is $4,000 more compared to 2019. Consumers end up spending on home improvements to make their homes more suitable for their lifestyles. So, the increasing spending on home remodelling is expected to propel the growth of the glass curtain wall market over the coming years. Low emissivity glass curtain wall is a key trend gaining popularity in the glass curtain wall market. Major companies operating in the glass curtain wall sector are focused on developing new technological solutions to strengthen their position. For instance, in February 2021, Vitro Architectural Glass launched Solarban R77 solar control, low-emissivity (Low-E) glass that combines a sharp, neutrally reflective silver-blue aesthetic along with the building-code-friendly solar performance. Vitro Glass created the glass to fill a specific gap in the company's portfolio, providing architects with a comfortable exterior-reflected colour that is more subtle than Solarban R100 glass but more defined compared to the reflective appearance of Solarban 67 glass. In August 2021, Dynamic Glass, a leading a US-based provider of glass, glazing, and metal panel services acquired Colorado Window Systems (CWS) for an undisclosed amount. This acquisition will help Dynamic Glass expand its glass and glazing portfolio with the main focus on enhanced service capabilities in Colorado. CWS is a key company in providing high-quality glass and glazing services to Colorado's top general contractors. Major players in the glass curtain wall market are Saint-Gobain, Asahi Glass, Central Glass Co., Ltd., Guardian Industries, Nippon Sheet Glass, Avic Sanxin Co., Ltd., Schott AG, China Glass Holdings Limited, Vitro, Xinyi Glass Holdings Limited., Apogee Enterprises, Inc., Kawneer, Arconic, Hansen Group Ltd., Heroal, Kalwall Corporation, and Yuanda China Holdings Limited. Asia-Pacific was the largest region in the glass curtain wall market in 2022. The regions covered in the glass curtain wall market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the glass curtain wall market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The glass curtain wall market consists of sales of tempered glass, and laminated glass curtain walls. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global glass curtain wall market is segmented - 1) By System Type: Unitized, Stick 2) By End-use: Commercial, Public, Residential 3) By Glazing Application: Exterior Glazed, Interior Glazed

Advanced packaging technologies refer to the technologies involved in the aggregation and interconnection of components before traditional electronic packaging. It allows integrated circuits to be enclosed in a casing, which prevents metallic parts from corroding and physical damage. The main types of advanced packaging technologies are 3D integrated circuits, 2D integrated circuits, 2.5D integrated circuits, and others. The 3D integrated circuit provides high bandwidth, a small form factor, and multi-function integration in packaging. Three-Dimensional Integrated Circuit (3DIC) is a packaging technology that collects and stacks homogeneous or heterogeneous dies vertically into Multi-Chip Modules (MCM) with Through-Silicon-Via (TSV). The various types of products include active packaging, smart and intelligent packaging and is implemented in various verticals such as automotive and transport, consumer electronics, industrial, IT and telecommunication, others. The advanced packaging technologies market research report is one of a series of new reports from The Business Research Company that provides advanced packaging technologies market statistics, including advanced packaging technologies industry global market size, regional shares, competitors with a advanced packaging technologies market share, detailed advanced packaging technologies market segments, market trends and opportunities, and any further data you may need to thrive in the advanced packaging technologies industry. This advanced packaging technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global advanced packaging technologies market size grew from $5.74 billion in 2022 to $6.52 billion in 2023 at a compound annual growth rate (CAGR) of 13.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, causing inflation across goods and services and affecting many markets across the globe. The advanced packaging technologies market size is expected to grow to $10.44 billion in 2027 at a CAGR of 12.5%. Growing demand for consumer electronics is expected to propel the growth of the advanced packaging market going forward. Consumer electronics refers to any electronic equipment, gadgets, or devices made to be purchased and used on a regular basis for non-commercial or professional purposes by consumers. Consumer electronics can create demand for advanced packaging as it plays an important role in defining the sophistication of the products. For instance, in June 2021, Oberlo, a Lithuania-based e-commerce platform, said that globally, 6.4 billion people use smartphones. Therefore, the growing demand for consumer electronics is driving the advanced packaging market. The growing technological advancements are shaping the advanced packaging technologies market. Major companies operating in the advanced packaging technologies sector are focused on developing technological solutions for advanced packaging to expand their leadership in semiconductor solutions. For instance, in May 2021 Samsung Electronics, a South Korea-based electronics company launched Interposer-Cube4 (I-Cube4), an advanced chip packaging technology for high-performance applications. Interposer-Cube4 (I-Cube4), a 2.5D packaging technology improves communication and power effectiveness among logic and memory chips and is projected to be widely used in sectors such as high-performance computing, artificial intelligence (AI), 5G, cloud, and the largest data center applicants. In December 2020, Graham Partners, Inc., a US-based private investment firm focused on investing in technology-driven companies acquired flexible packaging converting the business from Berry Global for an undisclosed amount. The flexible packaging converting business will be combined with Graham Partners’ flexible packaging portfolio company, Advanced Barrier Extrusions LLC. Through this acquisition, ABX expands geographically, adds attractive categories such as personal care and healthcare packaging, and increases its revenue by over $200 million, according to Graham Partners. Berry Global is a US-based manufacturer and marketer of advanced plastic packaging products. Major players in the advanced packaging technologies market are Amkor Technology, Intel, Advanced Semiconductor Engineering (ASE), Taiwan Semiconductor Manufacturing Company, Samsung Electronics, STATS ChipPAC, Qualcomm Technologies, IBM, Brewer Science, SÜSS Microtec, Renesas Electronics Corporation, Texas Instruments, Siliconware Precision Industries, Jiangsu Changjiang Electronics Technology, China WLCSP Co. LTD., Deca Technologies, Greatek Electronics, Powertech Technology, Sanmina Corporation, SFA Semicon, Universal Instruments Corporation, and Tongfu Microelectronics. Asia-Pacific was the largest region in global advanced packaging technologies market in 2022. The regions covered in the advanced packaging technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the advanced packaging technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The advanced packaging technologies market consists of revenues earned by entities by providing packaging services such as fan-out wafer-level packaging and system-in-package used during the process. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced packaging technologies market also includes sales of image sensor, microelectronics, complementary metal oxide semiconductor, light-emitting diode, design package, external cavity, ultraviolet light, and others which are used in providing packaging services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global advanced packaging technologies market is segmented - 1) By Type: 3D Integrated Circuit, 2D Integrated Circuit, 2.5D Integrated Circuit, Other Types 2) By Product: Active Packaging, Smart And Intelligent Packaging  3) By End Use Industry: Automotive And Transport, Consumer Electronics, Industrial, IT And Telecommunication, Other End Use Industries

Aseptic packaging is the process of packaging a beverage or food product at ultra high temperature (UHT), sterilizing or sanitizing the packaging separately, then fusing and sealing under sterile atmospheric conditions to avoid viral and bacterial contamination. The main types of aseptic packaging are cartons, bags and pouches, bottles and cans, ampoules, and others. Carton is a light box where products are stored, bags and pouches are used to carry different items in one pocket, bottles and cans are the containers used to store liquid items, and an ampoule is a sealed vial made of glass or plastic which contains a sterile medicinal solution or a powder. The aseptic packaging protects against bacteria, light and vapor and helps increase the shelf-life of the product. Aseptic bags and pouches are made using by polyethylene particles and offer low-temperature resistant performance, good chemical stability and electrical insulation properties. Aseptic bottles and cans are rendered ultra-high temperature (UHT) treatment for improving hygiene and shelf-life and are used widely in the dairy and beverages industries. Aseptic ampoules are small glass vessels sterilized to prevnst pathogens and are usedthe in pharmaceuticals and chemicals industry. The materials used in aseptic packaging are plastic, paper, paperboard, metal, glass, and wood. This aseptic packaging is used by food, beverage, pharmaceutical, and other industries. The aseptic packaging market research report is one of a series of new reports from The Business Research Company that provides aseptic packaging market statistics, including aseptic packaging industry global market size, regional shares, competitors with an Aseptic Packaging market share, detailed aseptic packaging market segments, market trends and opportunities, and any further data you may need to thrive in the aseptic packaging industry. This aseptic packaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global aseptic packaging market size grew from $64.07 billion in 2022 to $70.56 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The aseptic packaging market size is expected to grow to $107.81 billion in 2027 at a CAGR of 11.2%. The increase in demand for convenience food products with a longer shelf life and safe hygiene packaging is expected to drive the growth of the aseptic packaging market in the forecast period.For instance, the global processed snacks market is expected to increase from $96.9 billion in 2020 to $142.0 billion by 2025. Therefore, the growing demand for convenience and processed food drives the growth of the aseptic packaging market Companies in the aseptic packaging market are focusing on the development of single-use passive for ensuring maximum safety and reducing wastage. Single-use passive refers to transferring the contained and sterile contents between manufacturing process steps and facilities. It also creates an agile manufacturing environment and lowers the toxicity when mixing to make a final product, thus saving time and cost associated with cleaning, maintenance and validation. For instance, in June 2022, Greatview Aseptic Packaging Company, a China-based aseptic processing company, introduced aseptic cartons. This aseptic carton is derived from a biobased polymer utilized to produce the aseptic carton pack and laminate paper boards to improve sustainability in product packaging. In February 2022, Hewlett-Packard Company, a US-based information technology company, acquired Choose Packaging for $10 billion. Through this acquisition, HP, Inc. would increase recyclable packaging solutions and promote alternatives to plastic bottles while also advancing HP's more general sustainability objectives. Choose Packaging is a UK-based packaging company pioneering in the development of innovative packaging solutions and sustainable packaging alternatives to plastic, such as paper and paperboard, and pressure-sensitive materials that include aseptic packaging. Major players in the aseptic packaging market are Reynolds Group Holdings Limited, Amcor Limited, Tetra Laval International S.A, Greatview Aseptic Packaging Co. Ltd., Tetra Pak International SA, Sig Combibloc AG, SIG Combiboc Obeikan, ELOPAK Group, Sealed Air Corporation, DS Smith PLC., and UFlex Limited. Asia-Pacific was the largest region in the aseptic packaging market in 2022. Asia-Pacific is expected to grow faster in the forecast period. The regions covered in the aseptic packaging report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the aseptic packaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The aseptic packaging market consists of sales of bags & pouches, prefilled syringes, vials & ampoules, and other aseptic packaging. The products are placed into a container or packaging covered in a sterile environment. This method uses extremely high temperatures to maintain the freshness of the contents while ensuring it is not contaminated with microorganisms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global aseptic packaging market is segmented - 1) By Type: Cartons, Bags And Pouches, Bottles And Cans, Ampoules, Other Types 2) By Material: Plastic, Paper And Paperboard, Metal, Glass, Wood 3) By Application: Food, Beverage, Pharmaceutical, Other Applications

Pharmaceutical active pharmaceutical ingredients (API) manufacturing refers to the production of the active substances that give a pharmaceutical medicine its desired impact on the body to treat a condition. Chemical components must be processed in order to make APIs. A biologic drug's active component is referred to as a bulk process intermediate. The main therapy areas of pharmaceutical API manufacturing are cardiovascular disorders, metabolic disorders, neurological disorders, oncology, musculoskeletal disorders, NSAIDs, and other therapeutics uses. Cardiovascular diseases are a group of heart and blood vessel disorders. The various API type include chemical API and biological API that are used to produce innovative drugs, generic prescription drugs, and over-the-counter (OTC) drugs. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical active pharmaceutical ingredients (API) manufacturing market statistics, including pharmaceutical active pharmaceutical ingredients (API) manufacturing industry global market size, regional shares, competitors with a pharmaceutical active pharmaceutical ingredient (API) manufacturing market share, detailed pharmaceutical active pharmaceutical ingredients (API) manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical active pharmaceutical ingredients (API) manufacturing industry. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical api manufacturing market grew from $195.29 billion in 2022 to $209.93 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical api manufacturing market is expected to grow from $266.72 billion in 2027 at a CAGR of 6.2%. The rise in the aging population is one of the major drivers of the pharmaceutical API manufacturing market. As the aging population increases, the demand for pharmaceutical drugs also increases. API acts as a specialty drug in these medicines to cure a particular disease. For instance, in October 2022, according to an article shared by WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, 80% of senior citizens will reside in low- and middle-income nations by 2050. The population is aging considerably more quickly than in the past. In 2020, there will be more persons over the age of 60 than under five-year-olds. Therefore, rise in aging population is driving the growth of the pharmaceutical API manufacturing market. Stringent regulations for approval of pharmaceutical drugs act as a restraint on the pharmaceutical API manufacturing market. Various regions have their own set of rules, guidelines, and regulations set by their respective drug regulatory bodies. For example, in Japan, the manufacturers have to register an API with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) through the country’s Drug Master File (DMF) system. Products like APIs and new excipients i.e. inactive substances used in a drug should be registered compulsorily. The API manufacturer is also responsible for DMF registration, even if they don't have their office in Japan. They should appoint an in-country caretaker (ICC) to apply on their behalf. Also, if there are any changes to be made to DMF products, either an application for change in registration or a minor change notification should be submitted by the ICC to the PMDA. This whole process delays the drug approvals, thereby negatively affecting the pharmaceuticals API manufacturing market. Many companies use modern technologies such as process control, and powder handling to optimize API manufacturing. These technologies include advances in Lyophilization i.e. freeze-drying process. It is a low-temperature dehydration process that involves freezing the product, lowering pressure, and then removing the ice formed. For instance, Telstar, a company that manufactures efficient integrated systems for pharmaceutical and manufacturing processes, developed LyoGistics Zero, automatic loading and unloading system for freeze dryers to manufacture hazardous products. The system uses a linear magnetic driving mechanism that functions without racks and belts to reduce particle generation and this improves the hygiene in API manufacturing. Also, ILC Dover, a pharmaceutical company, developed the JetBreaker system, a semi-automatic powder handling system that separates powdered media and buffers powders so that they can be mixed better in a solution. In March 2021, Piramal Pharma Ltd., an India-based healthcare solutions company, acquired Hemmo Pharmaceuticals for an amount of $105.8 million. This acquisition is expected to expand PPS’s capacity to provide integrated services to its clients globally by gaining access to the expanding peptide API industry. The deal would also increase peptide API manufacturing and development capabilities. Hemmo Pharmaceuticals is an India-based developer and manufacturer of peptide APIs. Major players in the pharmaceutical API manufacturing market are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, PfizerInc., Aurobindo Pharma, Novartis AG, Dr. Reddy's Laboratories, Merck & Co.Inc., BASF SE., Bayer Healthcare, Mylan N.V., Albemarle Corporation, Actavis PLC., Hospira Inc., Ranbaxy Laboratories, Virbac, Zoetis, Heska Co., AbbVie Inc., AstraZeneca PLC., Eli Lilly and Company, GlaxoSmithKline PLC., Sanofi, Bristol-Myers Squibb, CiplaInc., and F. Hoffmann-La Roche Ltd. North America was the largest region in the pharmaceutical API manufacturing market in 2022. The Middle East is expected to be the fastest growing region in the global pharmaceutical API manufacturing market during the forecast period. The regions covered in the global pharmaceutical API manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical API manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market includes tablet, capsule, cream, and injectable sales.Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global pharmaceutical api manufacturing market is segmented - 1) By Therapy Area: Cardiovascular disorders, Metabolic disorders, Neurological disorders, Oncology, Musculoskeletal disorders, NSAIDs, Other therapeutics uses 2) By API Type: Chemical API, Biological API 3) By Drug Type: Innovative Drugs, Generic Prescription, Over-the-counter (OTC) Drugs

Sterile medical packaging refers to a packaging process of enclosing medical goods by using a material that is a non-reusable packing material that prevents the spread of microbes and reduces the chance of contamination. This packaging is intended to protect the sterility from the point of packaging until the time of use.   The main types of sterile medical packaging are thermoformed trays, sterile bottles and containers, sterile closures, pre-fillable inhalers, pre-fillable syringes, vials and ampoules, blisters and clamshells, bags and pouches, and wraps. The different materials used for manufacturing the packaging include plastics, glass, metal, paper & paperboard for use in pharmaceutical & biological, surgical & medical instruments, in-vitro diagnostic products, medical implants and other industries. The sterile medical packaging market research report is one of a series of new reports from The Business Research Company that provides sterile medical packaging market statistics, including sterile medical packaging industry global market size, regional shares, competitors with a sterile medical packaging market share, detailed sterile medical packaging market segments, market trends and opportunities, and any further data you may need to thrive in the sterile medical packaging industry. This sterile medical packaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global sterile medical packaging market size grew from $43.03 billion in 2022 to $47.43 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The sterile medical packaging market size is expected to grow to $69.15 billion in 2027 at a CAGR of 9.9%. The increased prevalence of infectious diseases and viruses has led to an increase in demand for sterile medical packaging to prevent any contamination, which is expected to contribute to the growth of the market. Infectious diseases are caused by infectious agents and can be passed from one person or animal to another. According to the WHO, in April 2021, globally, 150 million COVID-19 confirmed cases were reported, and 3.1 million deaths. The increased number of cases of infectious diseases has increased the demand for the sterile medical packaging market. Strict regulations with respect to the specifications and materials used by the firms in manufacturing sterile medical packaging are expected to restrain the market's growth. Compliance with the rules is required as a small flaw in the packaging can contaminate the product and endanger the life of a patient. For instance, the Food and Drug Administration (FDA) has established several sterilisation validation standards, such as the ISO 11137 consensus standard for radiation validation. Such standards necessitate specialised skills, resources, money, and time, which limits the growth of sterile medical packaging. Environmentally friendly packaging is an emerging trend in the sterile medical packaging market. Concerned about growing waste and plastic pollution in the oceans, medical product manufacturing companies are adopting sustainable business practices and showing an interest in the utilisation of packaging materials that are renewable and recyclable. Several pharmaceutical companies are switching to environmentally friendly sterile packaging to meet sustainability goals. For instance, in January 2021, AstraZeneca launched a sustainability plan worth $1 billion, with several sustainable packaging initiatives underway to reduce the carbon footprint by 2031. In September 2020, Johnson & Johnson's consumer health division invested $800 million through 2031 towards adopting future sustainable packaging solutions. In September 2022, Eastman Chemical Company, a US-based specialty chemical company, announced a strategic collaboration with Ethicon, Inc., a US-based surgical suture and wound closure devices manufacturing company. As a result of this collaboration, Ethicon is the first healthcare organization to employ medical-grade Eastman Renew materials in its product packaging. This is a crucial action to reduce waste in the healthcare system and advance the circular economy. Major players in the sterile medical packaging market are Amcor Limited, DuPont De Nemours and Company, 3M Company, West Pharmaceutical Services, Inc., Oliver Healthcare Packaging LLC, Placon Corporation, Oracle Packaging, Riverside Medical Packaging Company Ltd., Wipak Group, Steripack Ltd., BillerudKorsnäs, Techinipaq Inc., GS Medical Packaging Inc., Sonoco Products Company, Nelipak Healthcare Packaging, and Januaryco Inc. North America was the largest region in the sterile medical packaging market in 2022. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the sterile medical packaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The sterile medical packaging market includes revenues earned by entities by sterilizing medical goods such as syringes, needles, vials, and medical instruments to protect from microbial contamination. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global sterile medical packaging market is segmented - 1) By Material: Plastics, Glass, Metal, Paper & Paperboard, Other Materials 2) By Type: Thermoform Trays, Sterile Bottles & Containers, Sterile Closures, Pre-Fillable Inhalers, Pre-Fillable Syringes, Vials & Ampoules, Blister & Clamshells, Bags & Pouches, Wraps, Other Types 3) By Application: Pharmaceutical & Biological, Surgical & Medical Instruments, In-Vitro Diagnostic Products, Medical Implants, Other Applications 

Pharmaceutical contract development and manufacturing refers to a business that offers services for drug research and manufacture within the pharmaceutical sector. Using CDMOs as a partner, pharmaceutical companies can outsource medication development and production. Full-service drug development and manufacturing outsourcing companies (CDMOs) can handle every stage of the process and work with clients that want to outsource specific steps in their workflow. Everything is based on the requirements of each client. The main types of pharmaceutical contract development and manufacturing organisations (CMO) are active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, and secondary packaging. The active pharmaceutical ingredient (API) manufacturing includes the manufacturing of the part of any drug that produces the desired effects. The various research phases include preclinical, phase I, phase II, phase III, and phase IV. The different end-use sectors include big pharmaceutical companies, generic pharmaceutical companies, and small & medium-sized pharmaceutical companies. The pharmaceutical contract development and manufacturing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical contract development and manufacturing market statistics, including pharmaceutical contract development and manufacturing industry global market size, regional shares, competitors' pharmaceutical contract development and manufacturing market share, detailed pharmaceutical contract development and manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical contract development and manufacturing industry. This pharmaceutical contract development and manufacturing market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical contract development and manufacturing market grew from $122.31 billion in 2022 to $130.82 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical contract development and manufacturing market is expected to grow from $196.53 billion in 2027 at a CAGR of 10.7%. The growth of the pharmaceutical contract development and manufacturing market is driven by the increase in the demand for medicines across the globe. The high prevalence of diseases and the need for a longer lifespan increased the demand for medicines pushing the pharmaceutical companies to increase the production of existing drugs and raise the investment in their R&D to promote the development of new drugs. This impels the pharmaceutical companies to collaborate with contract manufacturing organizations (CMOs) as a way to lower operational costs, thus, increasing the demand for pharmaceutical contract development and manufacturing market. According to Alkermes PLC., a biopharmaceutical company indicates that pharmaceutical contract manufacturing will emerge as a strategic option for many companies ranging from very large to smaller specialty pharma entities and this mostly will happen because the pharmaceuticals companies are looking for cost-cutting. The pharmaceutical contract development and manufacturing market are restricted by the poor-capacity utilization of manufacturing facilities. The capacity utilization is calculated considering the full potential capacity of the production plant. The poor-capacity utilization of the production plant is caused due to the inefficiency of different sub-processes in the production line which results in low production. The low production output results in low revenue generation for the production unit, affecting the overall pharmaceutical contract development and manufacturing market. For instance, in January 2020, according to an article shared by Economic Times, an India-based English-language business-focused daily newspaper, The 1,500 API manufacturing facilities in India, according to the country's drug regulatory organisation, are only operating at 40% of their potential. Therefore, the usage of capacity of the production plant negatively affects the pharmaceutical contract development and manufacturing market. The companies in the pharmaceutical contract development and manufacturing market are investing in acquiring and forming alliances with other companies in the market. The pharmaceutical contract development and manufacturing companies are following the trend of merger and acquisition to expand their global market reach to meet the client needs, increase their production capabilities while maintaining cost efficiencies, and get access to the latest technology and new services. The high levels of merger and acquisition activities are resulting in the consolidation of the contract service providers. For instance, in July 2022, Pharma Nobis, a US-based provider of contract manufacturing and private label services, acquired Fagron’s U.S. contract manufacturing business for an undisclosed amount. Through this acquisition, Pharma Nobis is expected to offer contract manufacturing and private label services to American retailers and consumer healthcare corporations. 20% of the company will continue to be owned by Fagron. In August 2022, Catalent, Inc., a US-based provider of delivery technologies, development, and drug manufacturing, acquired Metrics Contract Services for $475 million. This acquisition is expected to improve Catalent's ability to work with highly potent chemicals while enhancing its expertise in integrated oral solid formulation research, production, and packaging to assist clients in streamlining and accelerating their processes. Metrics Contract Services is a US-based pharmaceutical contract development and manufacturing organization. Major players in the pharmaceutical contract development and manufacturing market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH, Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals, HAUPT Pharma AG, Kemwell Pvt. Ltd., Nipro Corp., NextPharma, Royal DSM N.V., Althea Technologies, Thermo Fisher Scientific Inc., Lonza Group Ltd., AbbVie Inc., Consort Medical PLC., Almac Group, Siegfried Holding AG, Evonik Industries AG, and Vetter Pharma International GMBH. North America was the largest region in the global pharmaceutical contract development and manufacturing market in 2022. The Middle East is expected to be the fastest growing region in the global pharmaceutical contract development and manufacturing market during the forecast period. The regions covered in the global pharmaceutical contract development and manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical contract development and manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical contract development and manufacturing market includes revenues earned by entities by providing drug development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global pharmaceutical contract development and manufacturing organisation (CMO) market is segmented - 1) By Type: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging 2) By Research Phase: Preclinical, Phase I, Phase II, Phase III, Phase IV 3) By End-User: Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small & Medium-Sized Pharmaceutical Companies